Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos

Regulatory Affairs
Return to: PBR Home | Regulatory Affairs

ARIAD receives US patent for ponatinib pan-BCR-ABL inhibitor

PBR Staff Writer Published 16 February 2012

ARIAD Pharmaceuticals has received a US patent which covers composition-of-matter patent protection for ponatinib, a pan-BCR-ABL inhibitor, through 22 December 2026.

The patent number 8,114,874 was entitled, Substituted Acetylenic Imidazo[1,2-B] Pyridazine Compounds as Kinase Inhibitors.

The new patent covers both the compound itself and its pharmaceutical compositions.

Additional patent applications covering ponatinib in the US and in other countries are pending, the company said.

ARIAD chairman and CEO Harvey Berger said they are preparing to file for US and European MAAs for use of ponatinib in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia patients.